The Food and Drug Administration (FDA) approved Zepbound in December 2024 for treating obstructive sleep apnea (OSA). Medicare Part D may cover Zepbound, but only when a doctor prescribes it for OSA.

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher-dose options, making the weight-loss drug ...

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.

Zepbound is the name of the first drug approved by the FDA for obstructive sleep apnea. According to the Mayo Clinic, obstructive sleep apnea is a common sleep-related breathing disorder that ...

Medicare should cover most types of sleep studies when they are necessary to diagnose sleep apnea. It may also cover certain studies to diagnose other sleep-related conditions. Polysomnographies ...

This major development ensures that eXciteOSA ® therapy can be more readily accessed by Medicare and Medicaid ... s mission to make root-cause sleep apnea solutions available to patients across ...

(Ivanhoe Newswire) --- Obstructive sleep apnea, or OSA, affects nearly a billion ... also known as Mounjaro or Zepbound. “It’s called GLP one receptor,” said Atul Malhotra, MD from the ...

Eligible patients diagnosed by a health-care provider with obesity alone or along with obstructive sleep apnea ... to pay for Zepbound themselves and are enrolled in Medicare or employer ...